Role of lactoferrin in treatment of bovine mastitis by Kutila, Taina
Role of Lactoferrin in Treatment of
Bovine Mastitis
Taina Kutila
Helsinki 2004
Department of Clinical Veterinary Sciences
Faculty of Veterinary Medicine
University of Helsinki
Finland
Role of Lactoferrin in Treatment of
Bovine Mastitis
Taina Kutila
ACADEMIC DISSERTATION
To be presented with the permission of
the Faculty of Veterinary Medicine, University of Helsinki,
for public criticism in Auditorium Maximum,
Hämeentie 57, Helsinki,
on March 12th, 2004 at 12 noon.
Helsinki 2004
4,!7IJ5C9-bgjehe!
5Supervisors Professor Hannu Saloniemi
Department of Clinical Veterinary Sciences
Faculty of Veterinary Medicine
Finland
Professor Satu Pyörälä
Saari Unit
Faculty of Veterinary Medicine
Finland
Docent Liisa Kaartinen
National Agency for Medicines
Finland
Reviewers Honorary Senior Reserch Fellow Jeremy Brock
Department of Immunology
University of Glasgow
Scotland
DVM, PhD, Professor Weihuan Fang
College of Animal Sciences/Institute of Preventive Veterinary
Medicine
Zhejiang University, Hangzhou
P.R. China
Opponent Professor Hannu Korhonen
MTT AgriFood Research
Finland
Chairman Professor Hannu Saloniemi
Department of Clinical Veterinary Sciences
Faculty of Veterinary Medicine
Finland
7Vaikka sinulla olisi älyä joutuisit aina pulaan ellei sinulla ole
sydäntä joka älyäsi ohjaa.
Maria Jotuni
Dedicated to the memory of my father
9TABLE OF CONTENTS
Page
ABSTRACT 11
ABBREVIATIONS 13
LIST OF ORIGINAL PAPERS 15
1. INTRODUCTION 16
2. REVIEW OF THE LITERATURE 18
2.1 Structure and mechanisms of action of lactoferrin 18
2.2 Antimicrobial activity of lactoferrin 19
2.3 Lactoferrin concentrations in bovine milk and udder secretions 21
2.3.1 Lactating and non-lactating healthy cows 21
2.3.2 Mastitic cows 23
2.4 Lactoferrin alone or in combination with antimicrobial drugs in
treatment of bovine mastitis 23
2.5 Treatment of coliform mastitis 25
3. AIMS OF THE STUDY 28
4. MATERIALS AND METHODS 29
4.1 Animals (I - IV) 29
4.2 Lactoferrin and citrate determinations (I, II) 29
4.3 Lactoferrin purification (II - IV) 30
4.4 Bacteria (II) 30
4.5 Analysis of bacterial growth by turbidometry (II) 31
4.6 Experimental designs (I - IV) 32
4.7 Clinical observations and collection of blood and milk samples
(III, IV) 33
4.8 Determination of indicators of inflammation in milk (I - IV) 34
4.9 Other methods (IV) 34
4.10 Statistical methods (I - IV) 35
10
5. RESULTS 36
5.1 Lactoferrin and citrate concentrations in milk and dry cow 36
 secretion (I)
5.2 Inhibitory activity of lactoferrin against udder pathogens (II) 36
5.3 Disposition kinetics of lactoferrin in lactating dairy cows (III) 37
5.4 Efficacy of lactoferrin in treatment of experimentally induced
           E. coli mastitis (IV) 39
6. DISCUSSION 42
7. CONCLUSIONS 49
ACKNOWLEDGEMENTS 50
REFERENCES 52
11
ABSTRACT
The non-specific, multifunctional glycoprotein lactoferrin (Lf) is present in milk
and external body secretions. It is released by the secondary granules of
neutrophils and epithelial cells in high concentrations in response to inflammatory
stimuli. Lf has a broad-spectrum antimicrobial activity, especially against
coliform bacteria, such as Escherichia coli, which cause severe mastitis in dairy
cows. Since treatment of severe coliform mastitis using antimicrobial agents is
problematic, Lf as a natural protein may offer an alternative for treating this
disease.
The aim of this work was to evaluate the usefulness of exogenic Lf in mastitis
treatment. First, normal concentrations of Lf and citrate in the early dry cow
secretion of healthy cows were studied. Second, the antimicrobial efficacy of Lf
against udder pathogens, particularly E. coli, was tested in vitro. Third, the
disposition kinetics of Lf infused into the udder quarters of dairy cows was
investigated. Finally, the antibacterial effect of Lf was studied in an experimental
E. coli mastitis model.
To determine the normal concentrations of Lf and citrate, milk and dry udder
secretion samples were collected on the last day of lactation before the drying-off,
and then 2 and 6 days later. The mean Lf concentration in the milk increased from
5.29 mg/ml on the last day of drying-off to 8.09 and 11.26 mg/ml 2 and 6 days
later, respectively. Citrate concentration decreased from 1.85 mg/ml to 1.54 and
1.09 mg/ml, respectively. Concentrations varied greatly between cows and even
between udder quarters at each time-point. Median molar ratio (citrate to native
Lf) decreased gradually from 153 on the last day of lactation to 44 on day 6 after
drying-off.
The antibacterial effect of Lf was tested in vitro against E. coli, Staphylococcus
aureus, and coagulase-negative staphylococci (CNS) as well as on Pseudomonas
aeruginosa and Klebsiella pneumoniae, originally isolated from bovine mastitis.
Concentrations of Lf used were 0.67, 1.67 and 2.67 mg/ml. The best inhibitory
activity of Lf was seen against E. coli and P. aeruginosa. The inhibitory effect of
Lf for E. coli was concentration-dependent, and variation between the five
isolates of E. coli was small. None of the isolates was totally resistant to Lf. The
growth of two isolates of P. aeruginosa was clearly inhibited in Iso-Sensitest
Broth, in contrast to two K. pneumoniae isolates, which were virtually unaffected.
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The isolates of CNS and S. aureus showed more variation in susceptibility to Lf
than E. coli. Three isolates of S. aureus were more susceptible to Lf than the two
other isolates at 0.67 mg/ml of Lf. The growth of four CNS isolates was
somewhat inhibited by Lf, but one isolate was totally resistant.
The disposition kinetics of Lf after intramammary administration was studied in
lactating dairy cows. A 1-gram dose of Lf produced elevated Lf concentrations in
milk for several hours. The mean elimination half-life of total Lf was 2.2 h, and
the mean maximum concentration of 6.3 mg/ml was reached between 1 and 4 h
post-infusion. The average Lf concentration in milk of six cows before
administration of Lf was 0.4 mg/ml. After 8 h of administration, the average Lf
concentration decreased to 0.8 mg/ml. Lf caused some local tissue irritation in the
udder quarters, but general signs, such as fever and anorexia, were not observed.
The udder quarters of primiparous cows seemed to react faster than those of
multiparous cows. The irritation reactions decreased more rapidly in older than in
primiparous cows.
In an experimental E. coli mastitis model, the clinical response to the challenge
varied markedly among individual cows. In general, systemic signs disappeared
within 2-3 days, and local signs within one week. Differences in systemic and
local clinical signs between Lf- and enrofloxacin-treated cows were not
significant. Bacterial counts in milk decreased faster in enrofloxacin- than Lf-
treated cows, the difference almost reaching significance. Bacteria were
eliminated from the challenged quarters of the enrofloxacin-treated cows within
3.8 days and Lf-treated cows within 5.8 days on average. Differences in somatic
cell counts between treatments were not significant. However, NAGase activity
remained high for a longer time in milk of cows treated with Lf than with
enrofloxacin. Daily and quarter milk yield profiles over the experimental period
were similar in both treatment groups.
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ABBREVIATIONS
aa Amino acid
Apo-Lf Iron-free lactoferrin
CFU Colony-forming units
CMT California Mastitis Test
CNS Coagulase-negative staphylococci
DELFIA Dissociation-enhanced lanthanide fluoroimmunoassay
E. coli Escherichia coli
IL-1 Interleukin-1
IL-2 Interleukin-2
IL-8 Interleukin-8
ISB Iso Sensitest Broth
i.v. Intravenous
K. pneumoniae Klebsiella pneumoniae
LAL Limulus amebocyte lysate
Lf Lactoferrin
LPS Lipopolysaccharide
MIC Minimum inhibitory concentration
NAGase N-acetyl-ß-D-glucosaminidase
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P. aeruginosa Pseudomonas aeruginosa
PC Post-challenge
PMN Polymorphonuclear neutrophils
S. aureus Staphylococcus aureus
s.c. Subcutaneous
SCC Somatic cell count
Str. agalactiae Streptococcus agalactiae
Str. dysgalactiae Streptococcus dysgalactiae
Str. uberis Streptococcus uberis
TNF-? Tumour necrosis factor alpha
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1. INTRODUCTION
Lactoferrin (Lf) is a component of the natural protection systems of humans and
animals. Non-specific, multifunctional Lf is present in milk and such external
secretions of the body as saliva, bile, tears and sperm. It is released by secondary
granules of neutrophils and epithelial cells in high concentrations in response to
inflammatory stimuli (Baggiolini et al. 1970, Harmon & Newbould 1980, Brock
1995, Lönnerdal & Iyer 1995, Nuijens et al. 1996, Aguila & Brock 2001, Plaffl et
al. 2003). Lf, “the red protein”, was first identified in 1939 in milk whey
(Soerensen & Soerensen 1939). Since the 1960s, scientists have studied its
structure, functions and potential applications. Today, scientists are still searching
for new ways to use Lf in the treatment of bacterial, viral and fungal infections,
sepsis, cancer and tumours and immunosupressory illnesses both in human and
veterinary medicine. Lf also has an application as a supplement in functional
foods for humans and animals like calves (Joslin et al. 2002, Roblee et al. 2003).
In 1995, Lohuis and co-workers suggested that Lf might have potential in the
treatment of bovine mastitis. Four years later, the Department of Process and
Environmental Engineering at the University of Oulu, Finland, started to develop
the absorption chromatography method for large-scale, reasonably priced Lf
purification from cheese whey. Production of bovine Lf had until this point been
expensive. In  autumn 1999, our group began to study the potential role of Lf in
the treatment of bovine mastitis. In economic terms, mastitis is generally
considered to be the most serious disease of dairy cows. Practical measures for
controlling intramammary infections caused by Staphylococcus aureus,
Streptococcus agalactiae  and, to a lesser extent, other streptococci have been
developed and are widely applied (Erskine et al. 1987, Lam et al. 1997). These
measures are less effective against mastitis, which is caused by Gram-negative
bacteria belonging to the normal flora of the gastrointestinal tract. Teat dipping
and dry-cow therapies do not help in the control of coliform mastitis, and clinical
coliform mastitis remains a problem. The trends towards loose housing, increased
herd size and crowding of cows tend to increase the coliform load in the
environment as well as the likelihood of infections (Hogan et al. 1989, Schukken
et al. 1990, Lam et al. 1997, Peeler et al. 2002).
The treatment of coliform mastitis is problematic because signs are due to the
response of bacterial endotoxin, but the effect of antimicrobial treatment is
questionable (Jones & Ward 1990, Pyörälä et al. 1994). In addition, the use of
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broad-spectrum antimicrobial drugs, such as fluoroquinolones, increases selection
pressure for development of resistant bacterial strains. Thus, antimicrobial
therapy is a dual-edged sword, and new treatment approaches are needed. We
decided to concentrate on Lf alone, without combining it with antimicrobial
drugs. There were several reasons for taking this approach. Public concern over
food safety is increasing, and people are more aware of the risk of using
antimicrobial drugs. Political and regulatory pressure against the wide use of
broad-spectrum antimicrobial drugs for dairy cattle has also increased. Lf as a
natural protein sidesteps these concerns.
Before taking Lf on board as a therapeutic agent, preliminary studies should be
undertaken. Improved knowledge of the physiological concentrations of Lf at
drying-off is necessary prior to Lf being used as a dry-cow product. The in vitro
efficacy of Lf against udder pathogens also requires additional studies to those
available (Oram & Reiter 1968, Arnold et al. 1980, Reiter 1985, Lönnerdal & Iyer
1995). The disposition kinetic character of exogenic Lf in the udder remains
unknown.
The nature of Lf and its potential use in the treatment of mastitis, especially
coliform mastitis, are discussed in the following review of the literature. The
structure and general mechanisms of action of Lf are briefly reviewed, and the
antibacterial properties are presented. Lf concentrations in milk of healthy and
mastitic cows are described. Lf as an alternative to antimicrobial and preventive
dry-cow therapies is discussed.  Finally, a general review of severe Escherichia
coli mastitis and problems associated with its treatment are provided.
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2. REVIEW OF THE LITERATURE
2.1 Structure and mechanisms of action of lactoferrin
Bovine Lf is a monomeric metal-binding glycoprotein synthesized as a 708-amino
acid (aa) protein with a 19-aa signal peptide (Mead & Tweadie 1990, Pierce et al.
1991). Lf consists of two globular lobes, each of which contains one iron-binding
site. These lobes, designated as the N- and C-lobes, represent the N- and C-
terminal halves of the polypeptide (Moore et al. 1997). The two metal-binding
sites of Lf that lie between the two domains of each lobe are highly similar to
each other (Moore et al. 1997) and to the corresponding sites in human Lf
(Anderson et al. 1989). Iron- binding occurs concomitantly with the binding of
two bicarbonate anions that appear to play a prominent structural role (Anderson
et al. 1989, Iyer & Lönnerdal 1993, Moore et al. 1997).
Lf serves an important function in the mammalian host defence mechanism
(Smith & Oliver 1981, Brock 1995, Nuijens et al. 1996) (Figure 1). It occurs in
external secretions, the secondary granules of neutrophils and epithelial cells
(Baggiolini et al. 1970, Harmon & Newbouls 1980, Brock 1995, Lönnerdal &
Iyer 1995, Nuijens et al. 1996, Aguila & Brock 2001), and is released by these
cells in higher concentrations in response to inflammatory stimuli. The
bacteriostatic activity of Lf depends on factors affecting iron binding, including
pH, certain ions and iron-sequestering mechanisms of bacteria. The effect of Lf
could be eliminated by saturating it with iron (Bullen et al. 1972), and at lower
pH values, the iron-binding capacity of Lf is lost (Mazurier & Spik 1980).
Besides bacteriostatic and bactericidal activities, Lf is a potent activator and
regulator of various immunological functions such as granulopoiesis (Sawatzki &
Rich 1989), cytokine production, antibody synthesis in vitro, natural killer cell
cytotoxicity, lymphocyte proliferation, complement activation and production of
interleukin (IL) -1, IL-2 and TNF-??(Sanchez et al. 1992, Brock 1995, Kimber et
al. 2002) (Figure 1). Lf may also participate in antitumour defence (Tsuda et al.
2002) and has been shown to have antiviral (Yasumura et al. 2002), antifungal
(Abe et al. 2002) and antiparasitic activities (Omata et al. 2001) (Figure 1). Baker
and co-workers (2002) suggested that Lf is a “moonlighting protein”, i.e. a protein
that has several distinct biological activities that manifest in different
environments.
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2.2 Antimicrobial activity of lactoferrin
Lf has broad-spectrum antimicrobial activity in vitro as well as in vivo against E.
coli, S. aureus, K..pneumoniae, Bacillus subtilis, Streptococcus mutans  and
Candida albicans, among others (Oram & Reiter 1968, Arnold et al. 1980, Reiter
1985, Zagulski et al. 1989, Lönnerdal & Iyer 1995, Bhimani et al. 1999).
However, the bacteriostatic activity against udder pathogens Streptococcus uberis
and Streptococcus agalactiae was unaffected (Rainard 1986, Fang et al. 2000).
Fang and co-workers (1999, 2000) postulated that binding to Lf could be one of
the mechanisms that virulent Str. uberis exploits to increase its pathogenicity in
intramammary infections since adherence to mammary epithelial cells was greatly
increased by addition of Lf in in vitro tests: Lf may act as a bridging molecule
between bacteria and mammary epithelial cells during Str. uberis mastitis.
However, the involvement of milk in Str. uberis adherence to bovine epithelial
cells may be complicated by other milk components that affect bacterial
interaction with epithelial cells (Fang et al. 1999).
Immunomodulator
Antiparasitic
Antifungal
Antiviral
Antibacterial
Activity
Protease
Protease Inhibitor
Ribonuclease
Procoagulant
Cationic Peptides
Autoantibodies
Granulopoiesis
Transcription
factor
Iron
Absorbtion
Hypoferraemia
Anti-Inflammatory
Antitumour
Lactoferrin
Figure 1. Proposed functions of lactoferrin (Brock 2002).
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The mechanism by which Lf inhibits bacterial growth has not been fully
elucidated. Its antimicrobial and anti-inflammatory effects are believed to be a
result of the powerful iron-chelating ability that makes iron unavailable to
bacteria (Reiter & Oram 1967, Weinberg 1978), thereby causing nutritional
deprivation in susceptible organisms. This argument is supported by the findings
that selected, highly virulent pathogens have evolved techniques to circumvent
this effect, either by secreting high-affinity low-molecular-weight iron chelators
(siderophores) that can compete with Lf, or by expressing Lf receptors, which are
highly species-specific (Ellison 1994, Brock 1995, Lin et al. 1998). Siderophores
are synthesized by many micro-organisms grown under iron-limited conditions.
They bind iron in the extracellular environment, then the iron-siderophore
complexes are actively bound by outer membrane receptors of bacteria, and the
iron is internalized (Neilands 1984, Neilands et al. 1985). Gram-negative bacteria
have as many as four high-affinity iron acquisition systems: aerobactin,
enterobactin, citrate and ferrichrome. The enterobactin iron acquisition system
has the highest affinity of all siderophores (Bagg & Neilands 1987. Lin et al.
1998, 1999); this iron acquisition system is composed of various enzymes that are
required for the synthesis and secretion of the siderophore enterobactin (Neilands
et al. 1985, Lin et al. 1998, 1999). The enterobactin receptor FebA participates in
transporting and deferrating ferric enterobactin. S. aureus bacteria also use
siderophores staphyloferrin A and B and aureochelin under iron-restricted growth
conditions (Modum et al. 2000, Diarra et al. 2002b). S. aureus isolated from
humans use transferrin, haemoglobin, ferroxamines and even Lf as sources of iron
in iron-restricted environment (Triever & Courcol 1996).
Evidence from a number of studies indicates that the antimicrobial activity of Lf
is more complex than simple Fe chelation. Lf has direct bactericidal activity and
can kill susceptible bacteria by a mechanism distinct from sequestering of Fe,
which is mediated through peptides known as lactoferricins (Arnold et al. 1980,
Dalmastri et al. 1988, Ellison et al. 1988, 1990, Brock 1995). The smaller size of
lactoferricins renders access to target sites on microbial surfaces easier than it is
for native Lf, which may explain the superior bactericidal effectiveness of
lactoferricin as compared with native Lf. By comparing minimal inhibitory
concentration (MIC) values on a molar basis, bovine lactoferricin was estimated
to be about 12-fold as effective against E. coli as undigested bovine Lf (Bellamy
et al. 1992). Bellamy and co-workers (1992) also found that the antimicrobial
domain is near the N-terminus of Lf, comprising parts of the N-terminal residues
1-48 of bovine Lf (Hoek et al. 1997), in a region distinct from Lf’s iron-binding
sites. Apo-Lf (iron-free form of Lf) was shown to alter bacterial cell membrane
function, or integrity and permeability, directly damaging the outer membrane of
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Gram-negative bacteria (Ellison et al. 1988, 1990, Bellamy et al. 1992, Yamauchi
et al. 1993, Appelmelk et al. 1994), by binding to lipopolysaccharide endotoxin
(LPS) and blocking its detrimental effects (Appelmelk et al. 1994). The bacterial
killing happened through osmotic damage, and the destabilization of the bacterial
cell wall is thought to occur through a non-specific binding of calcium and
magnesium to Lf (Ellison et al. 1988). LPS release was blocked by iron saturation
of Lf, and exogenous calcium and magnesium blocked the activity of Lf as well
(Ellison et al. 1988, 1990). The bacteriostatic form of Lf is either apo-Lf or partly
saturated Lf, while the fully Fe3+ -saturated form has no antimicrobial activity
(Bishop et al. 1976, Arnold et al. 1982). Approximately 6-8% of Lf in milk is
iron-saturated, which means that most of the Lf in milk is present in the apo-form
(Goldsmith et al. 1982).
Lf receptors have been identified on the surface of such bacteria as S. aureus and
CNS (Levay & Viljoen 1995). Lf has been suggested to bind to Lf receptors and
promote the activation of bovine complement via an alternative pathway, resulting
in a decrease in the number of staphylococci in the udder after infusion of Lf (Kai
et al. 2002b).
2.3 Lactoferrin concentrations in bovine milk and udder secretions
2.3.1 Lactating and non-lactating healthy cows
Lf is present in the colostrum and normal milk of most mammals (Masson &
Heremans 1971). Compared with other species, bovine milk and colostrum have
relatively low concentrations of Lf; the concentration varies from 0.02 to 0.35
mg/ml in the milk of healthy lactating cows (Welty et al. 1976) (Table 1). Lf
produced by the mammary gland may serve a dual role, protecting both the
mammary gland and the neonatal intestine from infection. Growth and
development of the gastrointestinal tract in newborn animals fed their dam’s milk
are known to be more rapid than in those fed commercial formula (Berseth et al.
1983, Heird et al. 1984, Widdowson 1985). Previous studies have shown that Lf
is a beneficial supplement in the diet of neonatal calves prior to weaning. Lf alters
the microbial populations in the gut of these non-ruminants and increases
preweaning weight gain (Joslin et al. 2002, Robblee et al. 2003).
Two to four days after cessation of regular milking, the concentration of Lf has
been shown to increase dramatically (Table 1). The linear increase continues at a
rate of about 1.15 mg/ml per day as a result of an increased net synthesis of Lf
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during the first 14 to 21 days of involution. After three to four weeks of
involution, the maximum Lf concentration (about 20 mg/ml) is achieved in the
udder secretion (Welty et al. 1976; Schanbacher et al. 1993). Lf concentrations
have increased, over 100-fold those in normal milk (Schanbacher et al. 1993), and
throughout the non-lactating period Lf concentrations remain high (Sordillo et al.
1987). Welty and co-workers (1976) also found that in some cows the
concentration of Lf was less than 10 mg/ml after 10 days of involution, whereas
much higher Lf concentrations in milk, 75 to 100 mg/ml (Table 1), were measured
in other cows. The dramatic increase in Lf concentrations after cessation of
milking appears to be a manifestation of the process of involution, while during
normal lactation Lf is a minor milk protein (Masson & Heremans 1971). The
interaction of Lf with other proteins such as immunoglobulin G or casein, in non-
lactating mammary secretions may affect the antimicrobial properties of Lf (Wang
& Hurley 1998); the fully involuted udder is very resistant to coliform infections,
mostly due to the high Lf content of the secretion (Oliver & Bushe 1987).
In the mammary gland, efficacy of Lf is negatively correlated with citrate content
of  milk (Bishop et al. 1976); citrate concentration varies greatly depending on the
time of lactation. It is at its highest after parturition and during mid-lactation (2.38
mg/ml), and at its lowest in the dry period (about 0.50 mg/ml) (Nonnecke and
Smith 1984a). Bicarbonate, which is required for the binding of iron by Lf, mole
per mole, can overcome the effect of citrate especially during the dry-cow period,
when citrate is absorbed from the udder secretion to blood, while bicarbonate
diffuses from blood to the udder secretion (Bishop et al. 1976, Griffith &
Humphrey 1977, Reiter 1985). The molar ratio of citrate to apo-Lf decreases with
udder involution and increases with lactogenesis (Smith et al. 1971, Peaker &
Linzell 1975). The molar ratio has been found to be more important in the
inhibition of the growth of Gram-negative bacteria in vitro than the absolute
concentration of either component (Bishop et al. 1976; Nonnecke & Smith
1984a). A citrate to apo-Lf ratio of 75 results in 50% growth inhibition of
coliform bacteria, whereas ratios of 300 and greater result in less than 10%
growth inhibition. In other words, the smaller the citrate to Lf molar ratio, the
more effective the inhibition of growth (Bishop et al. 1976). These results suggest
that the ratio of citrate to Lf is important in evaluating Lf as a non-specific
protective factor in bovine mammary secretions. Based on information available,
the citrate to Lf molar ratio would be more than 1000 in normal milk and
colostrum but only around 10 in the secretion of the fully involuted bovine
mammary gland. Nonnecke & Smith (1984a) found the mean molar ratio one
week before the dry period to be as high as 1154, declining to 28 two weeks after
the last milking.
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2.3.2 Mastitic cows
The mean concentration of Lf in the milk of cows with subclinical mastitis (0.2-
1.2 mg/ml) has been shown to be higher than in milk of normal cows (Hagiwara
et al. 2003) (Table 1). In addition, Lf concentration in subclinical mastitis might
depend on the pathogenicity of each bacterial species; the mean Lf concentrations
in milk from quarters infected with S. aureus or streptococci were significantly
higher than in milk from quarters infected with coagulase-negative staphylococci
(CNS) and Corynebacterium bovis (Hagiwara et al. 2003). In cows with clinical
mastitis, Lf concentrations in milk can range from 0.3 to 2.3 mg/ml (Table 1);
these concentrations are generally higher than in normal cows or those with
subclinical mastitis (Kawai et al. 1999, Hagiwara et al. 2003).
Kawai and co-workers (1999) reported that with peracute mastitis by E. coli, the
Lf concentration in milk was significantly lower than that from cows with acute
mastitis. Mean Lf concentration in milk from cows with peracute E. coli mastitis
was initially significantly lower than that  from cows infected with environmental
streptococci and CNS, but was elevated after 46 h from diagnosis of mastitis,
being higher than in mastitis caused by other pathogens (Harmon et al. 1975,
Kawai et al. 1999). The significant differences in Lf concentrations in milk from
normal cows and cows with subclinical and clinical mastitis may be associated
with the severity of inflammation or may depend on the virulence of the bacteria
involved. Kawai and co-workers (1999) also speculated that the lower Lf
concentration in quarters infected with E. coli might be insufficient to inhibit
bacterial growth because multiplication of E. coli in an inflamed udder quarter is
fast, while Lf concentration increases slowly in the early phase of inflammation.
2.4 Lactoferrin alone or in combination with antimicrobial drugs in the
treatment of bovine mastitis
Researchers have since the 1960s suggested that Lf with its broad-spectrum
antimicrobial effect would be a good candidate for a non-antibiotic treatment of
infections (Masson et al. 1966). Lohuis and co-workers (1995) and Diarra and co-
workers (2002a) later speculated that exogenous Lf infusion could potentially be
useful in the treatment of bovine mastitis, and could partly replace the use of
antimicrobials. Another application could be the prevention of mastitis at drying-
off (Kai et al. 2002b). Nickerson (1989) and Oliver & Sordillo (1989) pointed out
that the early period of mammary involution coincides with a period of increased
susceptibility to intramammary infection; endogenous Lf concentrations are low
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during this time. Clinical mastitis is, however, rare in the middle of the non-
lactating period (Nonnecke & Smith 1984a), when the concentration of Lf in
mammary gland secretion is at its highest (Welty et al. 1976). Kai and co-workers
(2002b) suggested the same as speculated here: administration of exogenous Lf
during early involution could help limit bacterial growth, not only for its
bacteriostatic and bactericidal effect, but also for the priming effects on the innate
immunity of the host. In addition, a high concentration of Lf promotes phagocytic
activity in the mammary gland and the activation of bovine complement (Kai et
al. 2002a). Lf could affect the disposition of apoptotic cells and bacteria during
the early non-lactating period, and exogenous Lf could thus be used as a dry-cow
therapy.
Pyörälä & Pyörälä (1998) investigated the efficacy of antimicrobial agents in the
treatment of clinical mastitis during lactation in a large retrospective study. They
showed that S. aureus infection is rather resistant to antimicrobial treatment,
especially when the isolates are penicillin-resistant and infections occur in older
cows. Diarra and co-workers (2002a) demonstrated a synergistic effect between
Lf and penicillin against three isolates of S. aureus from bovine mastitis, while Lf
alone showed a weak inhibitory activity. The ultrastructural alterations caused by
Lf to the bacteria enhance the activity of some antimicrobial agents (Sanchez &
Watts 1999, Diarra et al. 2002a), and by combining Lf with antimicrobial drugs to
treat infections, better results could be obtained than with antimicrobials or Lf
alone.
Lactation stage Lf concentration (mg/ml)  Reference 
Immediately after   about 2.4  Nonnecke & Smith 1984a
parturition              
Lactating cow  0.02 to 0.35   Welty et al. 1976
After 2 to 4 days  0.52 to 3.0   Welty et al. 1976
of involution 
After 5 to 7 days of  2.6 to 17.8   Welty et al. 1976
involution
After 10 days o  f ‹10 to 100 Welty et al. 1976, Schanbacher et al. 1993 
involution
Cows with subclinical   0.2 to 1.2 Kawai et al. 1999, Hagiwara et al. 2003
mastitis 
Cows with clinical mastitis 0.3 to 2.3 Harmon et al. 1976, Kawai et al.1999
Table 1. Concentration of lactoferrin in secretions of the bovine mammary gland
in healthy and mastitic cows.
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Phagocytosis by polymorphonuclear neutrophils (PMNs) and macrophages is an
important part of the host defence mechanism against pathogenic bacteria
(Vanfurth & van Zwet 1986). Many obligate and facultative intracellular bacteria
have developed sophisticated systems to avoid phagocytosis and intracellular
killing by phagocytic cells. In S. aureus, capsular polysaccharides contribute to
virulence by interfering with phagocytosis and intracellular killing by PMNs. For
these pathogens, the ability to survive in phagocytes and mammary epithelial cells
results in the persistence of infection and the failure of antimicrobial treatments
(Diarra et al. 2003). Ideally, synergism should exist between antimicrobial agents
and bactericidal activity of phagocytes to eliminate pathogens. Miyauchi and co-
workers (1998) reported that Lf enhanced phagocytosis by human neutrophils in
vitro. Diarra and co-workers (2003) suggested that if a similar effect exists in
dairy cows, Lf could be used to treat mastitis, especially during periods such as
early lactation, when the function of PMNs is depressed.
2.5 Treatment of coliform mastitis
Coliform mastitis, mostly caused by E. coli, is sometimes associated with severe
or even fatal systemic and local signs, and often causes considerably diminished
milk production (Golodetz 1985, Lohuis et al. 1990, Rantala et al. 2002); only
one-third of cows return to full lactation in the affected udder quarter (Golodetz
1985, Shpigel et al. 1997). McDonald & Anderson (1981) found that inactive
neutrophils were related to a high incidence of severe mastitis. The speed and
extent of the host response and the host’s resistance to infection largely determine
the prognosis of coliform mastitis, which in turn determines the recovery to
normal function (Paape et al. 2002, Burvenich et al. 2003).
During the puerperal period the mobilization and function of leucocytes, which
are important factors affecting the pathogenesis of coliform mastitis, may be
suppressed (Kehrli et al. 1989, Shuster et al. 1996). Compromised host response
in some cows can result in an exponential growth of E. coli bacteria and in
development of severe mastitis (Hirvonen et al. 1999, Burvenich et al. 2003). The
severity of mastitis has been demonstrated to be significantly related to bacterial
count in milk (Shuster et al. 1996, Hirvonen et al. 1999).  The higher the number
of viable bacteria in milk 10-12 hours after infection, which is when bacterial
numbers peak, the more severe the mastitis (Hill et al. 1984).
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Pyörälä & Pyörälä (1998) reported that the mean bacteriological cure rate for E.
coli mastitis was 71% and that spontaneous elimination of bacteria was typical.
However, this retrospective study contained all cases from mild to severe mastitis
during the lactation period, not only infections just after parturition. The
treatment of peracute and acute E. coli mastitis using antimicrobial agents is
problematic, and treatment results have been controversial (Jones & Ward 1990,
Katholm & Andersen 1992, Pyörälä et al. 1994a, Erskine et al. 2002), partly
because signs arise in response to LPS. In some experimental studies,
antimicrobial therapy was no more effective than no treatment at all (Jones &
Ward 1990, Pyörälä et al. 1994a). In other studies, however, antimicrobial
treatment in serious cases has resulted in faster elimination of bacteria, increased
survival rate of cows and reduction in the loss of milk production (Shpigel et al.
1997, Dosogne et al. 2002, Rantala et al. 2002). Antimicrobials continued to be
used to treat coliform mastitis despite the lack of convincing evidence for their
therapeutic value. Only a few antimicrobial substances are pharmacologically
suitable to treat coliform mastitis and are approved for use in lactating cattle.
Therefore, many broad-spectrum antimicrobials are used extra-labelly, which
increases the risk of drug residues both in milk and meat. The use of broad-
spectrum antimicrobials also increases selection pressure for development of
resistant bacterial strains.
In humans, the use of bactericidal drugs, such as gentamicin, to treat sepsis due to
Gram-negative bacteria may result in bacterial lysis, LPS release and shock (Goto
& Nakamura 1980, Shenep & Mogan 1984, Periti & Mazzei 1999). In bovine
mastitis, antimicrobial treatments of coliform mastitis have mostly failed to show
effective killing of bacteria (Jones & Ward 1990, Pyörälä et al. 1994a), and thus,
the risk for release of substantial amounts of LPS may be low. In a recent
experimental E. coli mastitis study, Dosogne & co-workers (2002) showed that
treatment with enrofloxacin was not associated with enhanced release of
endotoxin.
For treatment of coliform mastitis, in particular, new approaches are needed. Lf is
perhaps one of the most promising candidates. It could partly replace the use of
antimicrobials, and in addition, it has an LPS blocking effect. Zhang and co-
workers (1999) suggested that Lf could potentially be used to treat endotoxin-
induced septic shock in humans. Moreover, Zagulski and co-workers (1986)
showed that Lf increased survival rates in an experimental E. coli mouse model;
the mortality rate in the bovine Lf pretreated (24 hours before challenge) mice
was seven times lower than in control mice. In addition, bovine Lf given
intravenously (i.v.) to rabbits significantly prolonged survival time after systemic
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experimental infection with E. coli (Rainard 1986). While no studies have yet
been carried out using Lf to treat coliform mastitis in dairy cows, the results from
the above-mentioned experimental models are encouraging.
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3. AIMS OF THE STUDY
The main hypothesis and specific objectives of this study are presented in Figure 2.
LACTOFERRIN HAS 
THERAPEUTIC 
POTENTIAL IN MASTITIS 
Study I 
To describe the 
normal 
concentrations of 
Lf and citrate in 
the early dry 
secretion of 
healthy cows 
Study II 
To determine in
vitro the 
antibacterial 
activity of Lf 
against bovine 
udder pathogens 
Study III 
To study the 
disposition kinetics 
of Lf in milk as 
well as local and 
systemic tolerance 
of Lf in lactating 
dairy cows 
Study IV
To investigate the
efficacy of LF in
treating cows with
experimentally
induce E. coli
mastitis
Figure 2. The main hypothesis and the four objectives of the study.
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4. MATERIALS AND METHODS
4.1 Animals (I, III, IV)
Seventy clinically healthy Finnish Ayrshire and Friesian cows and one Finnish
landrace cow from the research farms of the University of Helsinki and MTT
Agrifood Research were used. Table 2 shows the number and types of the cows in
different experiments. In Study III, preliminary trials were conducted before the
final experiments.
.
4.2 Lactoferrin and citrate determinations (I, II)
Lf concentrations in the samples were determined using DELFIA (dissociation-
enhanced lanthanide fluoroimmunoassay) at the University of Oulu, Finland
(Isomäki 1999).
Concentration of citrate in the samples was measured by photometry (Mutzelburg,
1979) using a commercial kit (Boehringer Mannheim GmbH, Mannheim,
Germany).
Table 2. Number and types of cows used in the experiments
Study         Preliminary experiments Final experiments
I 19 primiparous and 29 multiparous cows
III 2 late lactating cows, mean 6 mid lactating cows (3 primiparous  
milk yield 12 l/day and 3 multiparous), mean milk
3 mid lactating cows, mean yield 25 l/day
milk yield 35 l/day 
IV - 6 early lactating, primiparous cows,      
mean milk yield 23 l/day
-
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The molar ratios were calculated using the following formula:
Molar ratio=
(average citrate concentration) / (molecular weight of citrate)
(average Lf concentration) / (molecular weight of Lf)
Molecular weight of citrate is 192 g/mol and that of Lf 77 000 g/mol.
4.3 Lactoferrin purification  (II-IV)
Lf was purified from cheese whey or concentrated cheese whey at the University
of Oulu, Finland, using an expanded bed adsorption chromatography method
developed by Isomäki (1999), and freeze-dried Lf was stored at 21°C. The
amount of endotoxin in Lf was tested with LAL (Limulus amebocyte lysate) using
the kinetic BioWhittaker-QCL method (Walkersville, MD, USA); it did not
exceed 1.7 ng/ml. Before udder infusion, Lf was sterile-filtered (32 mm Acrodisc
PT Syringe Filters 0.8/0.2 µm, Gelman Laboratory REF: 4658).
4.4 Bacteria (II)
Five isolates of E. coli, S. aureus and CNS, and two isolates of P. aeruginosa and
K. pneumoniae, originally isolated from subclinical or clinical cases of bovine
mastitis, were used. These isolates were received from the mastitis laboratory of
the Faculty of Veterinary Medicine and from the National Veterinary and Food
Research Institute, Helsinki. One of the S. aureus isolates was reference isolate
M60 kindly provided by Dr. A. J. Guidry (Immunology and Disease Resistance
Laboratory USDA, Beltsville, MD, USA).
During the experiment bacteria were maintained on blood agar plates at 8°C. To
adapt the bacterial isolates to grow in whey, they were incubated overnight at
37°C in a growth medium consisting of 2/3 Iso Sensitest Broth (ISB CM473,
Oxoid Ltd., Basingstoke, Hampshire, England) and 1/3 sterile whey. The cultures
were tested using Gram-staining for purity. Bacteria were harvested by
centrifugation (5000 g for 10 min) and washed twice between centrifugations
using sterile saline (0.9% NaCl, 20°C). A suspension containing approximately
109 colony-forming units (CFU) in 0.9% NaCl was prepared, according to the
McFarland standard (bioMérieux sa, 69280 Marcy I´Etoile, France), by
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spectrophotometry (550 nm, Hitatchi U-2000, Hitachi, Ltd., Tokyo, Japan).
Bacterial suspension was diluted to the final concentration of 1.5x103 CFU/ml
used in each well.
Two growth media were used for bacterial cultures: ISB and whey. Whey was
prepared from three lits of fresh raw milk obtained from the university dairy herd
by high-speed centrifugation of defatted milk (32600 g for 60 min at 4°C). Whey
was sterile-filtered and frozen in 40-ml aliquots immediately after preparation for
later use.
4.5 Analysis of bacterial growth by turbidometry (II)
The antibacterial effect of Lf was tested by using turbidometry (Bioscreen
instrument, Labsystems, Helsinki, Finland). The instrument is a fully automated
analysing system for measuring bacterial growth using the vertical light path with
the wide-band absorption principle; 200 samples can be measured simultaneously.
Each well contained 100 µl of ISB broth or 150 µl of whey as the growth
medium, 50 µl of bacterial suspension and 50 µl of Lf concentrate. Physiological
saline was added to bring the final volume to 300 µl: 50 µl and 100 µl in ISB and
whey wells, respectively. Tested amounts of Lf were 200 µg (final Lf
concentration in the well was 0.67 mg/ml), 500 µg (1.67 mg/ml) and 800 µg (2.67
mg/ml). Control wells contained all components except Lf, which was replaced
by 50 µl of 0.9% NaCl. Five parallel wells were used. Wells between whey and
ISB were filled with 0.9% NaCl to prevent cross-contamination. The wells on two
100-well plates were covered and preincubated in the Bioscreen instrument for 30
min at 37°C. The change in turbidity was monitored automatically every hour for
20 h at 37°C. The plates were shaken 10 min before each measurement.
Lag time (time from beginning of incubation until the time-point when
absorbance began to increase), slope (slope of the growth curve in the logarithmic
growth phase) and maximum absorbance (highest absorbance value measured
during the 20-h period) were used as variables describing the bacterial growth.
After the 20-h incubation period, bacterial survival and bactericidal effect of Lf in
the wells were confirmed by culturing aliquots of 10 µl on blood agar plates and
incubating the plates overnight at 37°C.
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4.6 Experimental designs (I, III, IV)
Study I, milk and dry udder secretion samples for the determination of Lf and
citrate concentrations were collected on the last day of the drying-off process, and
2 and 6 days later. The drying-off process lasted 2 weeks and was initiated
approximately 8 weeks before parturition. During this period the cows were
milked only once a day during the first week and once every second day during
the second week. The somatic cell count (SCC) was less than 250 000 cells/ml
milk in all except four cows, which had earlier had subclinical mastitis. Aseptic
milk samples cultured had less than five colonies of minor pathogens (mostly
Corynebacterium sp.) in some cows. Because these pathogens are considered to
be of minimal importance in mastitis (Oliver & Juneja 1990), we included these
cows in the experiment. The samples were frozen at –20°C, and Lf and citrate
concentrations were measured 4 to 7 months later as described earlier.
Study III, a 1-g dose of Lf was infused into one udder quarter of six cows after the
morning milking. Before udder infusion, Lf was dissolved in water and sterile-
filtered (32 mm Acrodisc PT Syringe Filters 0.8/0.2 µm, Gelman Laboratory
REF: 4658). Infusion volume was 91 ml, and the final Lf concentration 11 mg/ml.
Aseptic milk samples were taken before infusion and at 1, 2, 4, 8, 24 and 48 h
after infusion from test and contralateral control quarters. Milk was cultured for
bacterial growth at 24 and 48 h. The milk samples were frozen at –20°C, and Lf
concentrations were measured 2 weeks later. An aliquot of milk was separated
and used for determination of N-acetyl-ß-D-glucosaminidase (NAGase) activity.
NAGase was used as an indicator for inflammation in the milk. Pharmacokinetic
parameters of Lf were calculated using a commercial software package (PK
Solution 2.0.4, Non-compartmental Pharmacokinetic Data Analysis, SUMMIT
Research Services, Ashland, USA).
In Study IV, one udder quarter of each cow was infected via the teat canal with
approximately 1500 CFU of E. coli strain FT238 from clinical mastitis suspended
in 10 ml of pyrogen-free saline 4 h after evening milking. The strain was non-
haemolytic, intermediately serum-resistant and sensitive to enrofloxacin in vitro
(MIC <0.25 mg/ml) (Pyörälä et al. 1994a, Rantala et al. 2002). The strain was
also included in the in vitro testing for Lf (Study II) and found to be fully
susceptible to Lf. Treatment was started at 12 h post-challenge (PC), after the
morning milking, when clinical signs became visible. Three of the cows received
Lf three times (Table 3). The remaining three cows received enrofloxacin
(Baytril®, Bayer AG, Leverkusen, Germany) three times (Table 3). Flunixin
meglumine (Finadyne®, Schering-Plough, Farum, Denmark) was administered
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intravenously (i.v.) to all cows (Table 3). A cross-over design was used so that
each cow served as its own control (Hirvonen et al. 1999), and a contralateral
udder quarter of the same cow was inoculated at the second challenge.
4.7 Clinical observations and collection of blood and milk samples (III, IV)
In Study III, cows were carefully monitored post-infusion for possible adverse
reactions to the Lf infusion. The udder reactions were recorded on a four-point
scale (0 = no pain, no oedema; 1 = slight soreness, slight oedema; 2 = moderate
soreness, moderate oedema; 3 = severe pain, severe oedema, marked increase in
size). Rectal temperature was measured and possible systemic signs, such as
reduced appetite or depression, and the appearance of milk were recorded at the
same time-points.
In Study IV, systemic and local clinical signs of the cows were monitored
throughout the experiment; during the first 2 days every 4 h, and thereafter, every
time the cows were milked. Heart rate, rectal temperature, rumen motility,
appetite and general attitude were recorded. The udder was palpated for soreness,
swelling and hardness, and quarter milk samples were evaluated visually for
Table 3. Six dairy cows were divided in two treatment groups A and B. Number 1 refers to
the first challenge in one udder quarter and number 2 to the second challenge of the other
udder quarter three weeks later
Group  Route and times of administration after each challenge  
(n=3)  1.5g of Lf       5 mg/kg of En        2.2 mg/kg of Fl 
A1  i.m.     -             i.v. 12, 36 h 
  12, 20, 36 h  
B1  -            i.v. 12 h, s.c. 36 and 60 h       i.v. 12, 36 h 
A2  -            i.v. 12 h, s.c.  36 and 60 h      i.v. 12, 36 h 
B2  i.m.     -             i.v. 12, 36 h 
  12, 20, 36 h  
Lf, lactoferrin; En, enrofloxacin; Fl, flunixin meglumine.
i.m., intramammarily; i.v., intravenously; s.c., subcutaneously
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clotting, colour changes and serousness at each milking (Pyörälä et al. 1994a).
Local and systemic signs were scored on a three-point scale (1 = no signs to 3 =
severe signs) (Pyörälä et al. 1994a). Total daily milk yield was measured
throughout the study.
In Study IV, blood samples were drawn from the jugular vein of each cow. Blood
was collected at 12 h before challenge and again at 12, 16, 20, 36, 60, 84 and 180
h PC. Serum was separated and samples were frozen at -70°C for later use.
Aseptic milk samples were collected from the challenged and the contralateral
quarters 5 days and 12 h before the challenge and at 12, 16, 20, 36, 40, 44, 60, 84,
108, 132 and 156 h and 1, 2 and 3 weeks PC for bacteriology, SCC and NAGase
determination.
4.8 Determination of indicators of inflammation in milk (I, III, IV)
The California Mastitis Test (CMT) and determination of milk NAGase activity
were used as indicators of inflammation in the infused quarters. In the CMT, the
Scandinavian scoring system was used (Klastrup 1975). NAGase activity was
analysed using a microplate modification developed by Mattila & Sandholm
(1985) from the fluorogenic method of Kitchen and co-workers (1978). SCCs in
milk were measured using the Coulter Counter method (Mattila 1985).
4.9 Other methods (IV)
In the experimental challenge study (Study IV), the E. coli strain FT238 was used
for the challenge. The bacterial strain, which had been kept frozen, was cultured
and grown on blood agar plates overnight. A few colonies were subcultured in
ISB broth (Iso Sensitest Broth, Oxoid, Basingstoke, Hampshire, England) and
incubated for 18 h at 37°C. The broth culture was centrifuged at 4000 rpm (2800
x g) for 10 min, and the pellet was resuspended in sterile saline. The bacteria were
washed three times in saline and diluted to an estimated concentration of 108
CFU/ml. The final concentration was determined by measuring turbidity at 620
nm. The inoculation dose of approximately 1500 CFU was suspended in 10 ml of
pyrogen-free saline. After the challenge, bacterial counts in milk were determined
by preparation of a 10-fold dilution series of milk in sterile saline. Bacteria were
then cultured on blood agar, incubated at 37°C for 24 h and counted.
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The amount of endotoxin (LPS) in the milk samples of Study IV at 20 h PC was
measured using a LAL test as described in section 4.3. The ratio between the
amount of endotoxin and the bacterial count was calculated for both treatment
groups.
The concentration of Lf in the milk of infected udder quarters was not measured
because the consistency of the milk changed considerably after acute mastitis had
developed, and clots and flakes in milk have a marked effect on results.
Furthermore, separating endogenous and exogenous Lf is impossible.
4.10 Statistical methods (I-IV)
In Study I, temporal patterns in Lf and citrate concentrations, and differences
between the two breeds and between parities were tested by repeated
measurement analysis of variance. Each udder quarter was considered to be an
independent sampling unit. The cows were grouped into three parities:
primiparous cows, cows that had calved twice and cows that had calved three or
more times. As data on the molar ratio of  individual quarters of an udder were
skewed, median values were used in the statistical analysis. Significance of
within-subject effects were evaluated by Greenhouse-Geisser adjusted p-values,
and p-values less than 0.05 were considered significant. Friedman´s non-
parametric analysis of variance was used when testing changes in molar ratios
during the experiment.
In Study II, the effect of different Lf concentrations on lag time, slope and
maximum absorbance was tested by repeated measures analysis of variance with
concentration as a within-factor. The significance of concentration was evaluated
by Greenhouse-Geisser adjusted p-values. Concentrations of 0.67, 1.67 and 2.67
mg/ml were further compared with a negative control.
In Study IV, repeated measures analysis of variance with treatment and sampling
time as within-factors was used to test differences in variables (SCC, NAGase
activity, bacterial counts, systemic and local clinical signs, and total and quarter
milk yields) between the two treatments. The significance of effects was
evaluated by using Greenhouse-Geisser adjusted p-values. Possible carry-over
effects were assessed by T-test procedures (Jones & Kenward 1989). Statistical
significance of the ratio of endotoxin to bacterial count was determined using the
Wilcoxon Signed Ranks Test.
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5. RESULTS
This section summarizes the main findings. For more detailed results, the reader
should refer to the original papers located at the end of the thesis.
5.1 Lactoferrin and citrate concentrations in milk and dry cow secretion (I)
Mean Lf concentration increased while mean citrate concentration decreased in
milk and dry udder secretion during the sampling period. The concentrations of
both were highly variable at each time-point. Mean lactoferrin concentration in
milk increased from 5.29 mg/ml on the last day of the drying-off process to 8.09
and 11.26 mg/ml 2 and 6 days later, respectively, and citrate concentration
decreased from 1.85 mg/ml to 1.54 and 1.09 mg/ml, respectively. No significant
difference was found in Lf or citrate concentrations between the two breeds or
between different parity groups.
Median molar ratio of citrate to native Lf decreased from 153 to 86 and further to
44. This difference was statistically significant (p<0.01).
5.2 Inhibitory activity of lactoferrin against udder pathogens (II)
The best inhibitory activity of Lf in the ISB was seen against E. coli and P.
aeruginosa. The inhibitory effect of Lf for E. coli was concentration-dependent
(Figure 3), and variation in the effect against the five isolates of E. coli was small.
None of the E. coli isolates was totally resistant to Lf. The effect of Lf on the
maximum absorbance and the slope of E. coli in ISB was significant (p=0.025 and
p<0.001, respectively), whereas the effect on lag time was not (p = 0.065). The
growth of two isolates of P. aeruginosa was clearly inhibited in ISB. By contrast,
the growth of two K. pneumoniae isolates was hardly inhibited at all. In whey, K.
pneumoniae showed variable susceptibility and the results were contradictory.
The isolates of CNS and S. aureus in ISB showed more variation to Lf than did E.
coli. Lf had significant effects on lag time (p=0.014) and maximum absorbance
(p=0.014) of S. aureus, while no significant effects were seen for CNS. For to the
slope, a significant difference was present between Lf treatments and the control
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in the growth of S. aureus (p=0.001) and CNS (p=0.002). The growth of four
CNS isolates was somewhat inhibited by Lf, but one was totally resistant. Three
isolates of S. aureus were more susceptible to Lf than the other two isolates at
0.67 mg/ml of Lf. Lf treatment had a significant inhibitory effect on lag time
(p=0.015), maximum absorbance (p=0.011) and slope (p=0.027) of S. aureus in
whey. The isolates of E. coli, P. aeruginosa and CNS did not grow sufficiently
well in whey to draw any conclusions. We also conducted limited in vitro testing
using Apo-Lf (data not shown) and the results were comparable with those of
native Lf.
5.3 Disposition kinetics of lactoferrin in lactating dairy cows (III)
Intramammary administration of Lf produced elevated Lf concentrations in milk
for several hours (Figure 4). Mean elimination half-life of total Lf in milk was 2.2
(range 1.2-4.3) h. The mean maximum concentration of 6.3 (3.0-12.3) mg/ml was
reached between 1 and 4 h post-infusion. The average Lf concentration in milk
from six cows before the administration of Lf was 0.4 (0.1-1.1) mg/ml. Four
hours after infusion, two different patterns were seen; cows 1-3 in first lactation
had lower Lf concentrations than the older cows 4-6 (Figure 4). After 8 h of
administration, the average Lf concentration had decreased to 0.8 (0.2-1.6) mg/
ml. Twenty-four hours post-infusion, Lf started to increase again, and 48 h after
infusion, the mean Lf concentration was 1.5 (0.7-2.7) mg/ml. The increase was
lower in primiparous than in multiparous cows.
without LF 0.67 mg/ml of LF 2.67 mg/ml of LF
Figure 3. Inhibitory activity of lactoferrin (Lf) against Escherichia coli was clearly seen.
Ten microlitres of suspensions from wells after a 20- h incubation in Iso Sensitest Broth
without Lf and with 0.67 mg/ml and 2.67 mg/ml of Lf were spread onto blood agar plates
and incubated at 37°C for 24 h
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Lf caused some local tissue irritation in the udder quarters (Figure 5), but
systemic signs, such as fever or anorexia, were not observed. The udder quarters
of primiparous cows seemed to react faster than those of multiparous cows. The
severity of the reactions varied between cows and became visible 2 to 4 h after
infusion. In all but one cow, the infused udder quarters became hard or swollen.
In the same cows, the ipsilateral quarters swelled slightly. Four to eight hours
after administration of Lf, the local reactions reached their peak. The reactions
decreased more rapidly in older than in primiparous cows (Figure 5). At 24 h
post-infusion, the udder quarters of multiparous cows were normal, while
primiparous cows took 48 h to return to normal state. No bacteria were isolated
from milk samples taken 24 and 48 h after  administration of Lf.
The CMT score, indicating the number of cells in the milk of the infused quarters,
increased within 8 h of administration and then started to decrease 2 days post-
administration. As estimated using CMT, SCC returned to normal levels within 4
days of the infusion. Milk NAGase activity increased after the administration of
Lf, the highest value attained being 120 (from 48 to 120) arbitrary units/ml in one
cow. NAGase activity of less than 18 is equivalent to SCC of less than 300 000
cells/ml (Myllys et al. 1998).
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Figure 4. Lactoferrin (Lf) concentrations (mg/l) in milk after infusion of 1 g of Lf into one
udder quarter of three primiparous (1, 2 and 3) and three multiparous  (4, 5 and 6) cows.
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5.4 Efficacy of lactoferrin in treatment of experimentally induced E. coli
mastitis (IV)
All cows became infected with E. coli, and all developed clinical mastitis within
12 h PC. The clinical response varied greatly among individual cows. Statistically
significant carry-over effects from the first challenge to the second challenge
were not detected in any of the variables investigated. According to clinical
observations, the response of cows tended to be milder in the second challenge;
five cows during the first challenge and one cow during the second challenge
developed severe systemic signs of mastitis. Systemic signs generally disappeared
within two to three days, and local signs within one week. Differences in systemic
and local clinical signs (Figure 6) between Lf- and enrofloxacin-treated cows
were not significant.
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Figure 5. Irritation reactions in the udder after administration of lactoferrin (Lf). Cows 1,
2 and 3 were primiparous and cows 4, 5 and 6 were multiparous.
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Bacterial counts in the milk decreased faster in enrofloxacin- than Lf-treated
cows, the difference almost reaching significance (p=0.054) (Figure 6). Bacteria
were eliminated from the challenged quarters of enrofloxacin-treated cows on
average in 3.8 (median 5) days and from Lf-treated cows in 5.8 (median 6) days.
After the second challenge, the three cows in the enrofloxacin treatment group
had very low bacterial counts in milk already at the first sampling at 12 h PC.
Average bacterial count, average amount of endotoxin and the corresponding ratio
of the amount of endotoxin to the number of bacteria in milk 20 hours PC are
shown in Table 4. The corresponding ratios of the concentration of LPS to the
number of bacteria in milk for the enrofloxacin- and Lf-treated cows were
statistically significant (p = 0.028).
Milk SCCs of the challenged quarters were high at 12 h PC, after which they
decreased in all cows. After the first challenge, the SCCs of two cows, one from
the enrofloxacin-treated group and the other from the Lf-treated group,
approached pre-infection counts within 2 weeks PC. After the second challenge,
the SCCs of all enrofloxacin-treated cows and those of one Lf-treated cow
returned to pre-infection counts within 2 weeks. Differences in SCCs between
treatments were not statistically significant. Milk NAGase activity remained high
for a longer period in cows treated with Lf than in enrofloxacin-treated cows
(p=0.046) (Figure 6). The mean decrease in total daily milk production at one day
PC was similar for enrofloxacin- and Lf-treated cows: 23.8% and 24.1%,
respectively. Daily and quarter milk yield profiles over the experimental period
were also similar for both treatment groups (Figure 6).
Table 4. Average bacterial count, average amount of LPS and the corresponding ratio of
the amount of LPS to the number of bacteria in milk for enrofloxacin- and Lf-treated
cows with experimentally induced E. coli mastitis at 20 h PC.
Bacterial count Amount of LPS
Group (CFU/ml) (EU/ml) Corresponding ratios*
Lf treated1. 3x108 3.3x10 2.6x10 4
Enrofloxacin
treated 8.9x103 3.3x10 3.7x10 1
*  (p = 0.028).
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Figure 6. Score for mean (± standard error of mean) local signs, daily milk yield, milk
NAGase activity and milk bacterial counts of the infected quarters in lactoferrin (Lf) and
enrofloxacin (Enro) -treated cows. The data are combined from two successive challenges
carried out 3 weeks apart in six cows after infusion of 1500 CFU of E. coli into a single
udder quarter. Lf (1.5 g) was infused into the infected quarter at 12, 20 and 36 h post-
challenge (PC). Enro (5 mg/kg) was injected at 12, 36 and 60 h PC
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6. DISCUSSION
Bovine Lf may have potential in the prevention of bovine mastitis at drying-off,
as well as in the treatment of lactating cows. The idea for using Lf for dry cow
therapy is to protect the udder with exogenous Lf against new infections during
the involution period, when the cow’s own Lf concentration is still low. During
this period the total daily production of Lf by the mammary gland typically
increases at least two-fold that of the day of drying-off (Welty et al. 1976).
However, endogenous Lf concentrations are still quite low, and citrate
concentrations high. During the first two weeks of the dry period, the risk for
mastitis is many times higher than during the lactating period (Smith et al. 1985,
Nickerson 1989, Oliver & Sordillo 1989), probably due to cessation of milking,
which provides a better environment for bacteria to multiply in the milk
compartment of the udder. In the first part of this thesis the natural concentrations
of Lf and citrate were determined during the early drying-off period, because dry
cow therapy was one of the suggested indications for Lf.
Lf and citrate concentrations varied between cows, in agreement with the findings
of Welty and co-workers (1976); neither breed nor parity affected Lf or citrate
concentrations or changes in these concentrations over time. In addition, variation
in Lf and citrate concentrations was high between udder quarters of individual
cows. One explanation given for between-quarter variations is previous mastitis
in some of the udder quarters, but we were unable to verify this. Another more
plausible explanation is reduction in secretory activity of the mammary gland and
decline in milk volume for reasons other than previous mastitis (Smith &
Schanbacher 1977, Watson 1980). Reduction in milk production of individual
cows, and between udder quarters, differs before drying-off. Tsuji and co-workers
(1990) found out that 24 h after parturition colostrum from dairy breeds contained
on average four times more Lf than colostrums from beef breeds, and in
multiparous dairy cows Lf content in colostrum was two to three times higher
than in primiparous cows.
Another interesting finding was that the molar ratio of citrate to Lf, which has
been found to be more important in the inhibition of growth of Gram-negative
bacteria in vitro than the absolute concentration of either component alone
(Bishop et al. 1976, Nonnecke & Smith 1984), decreased from a median of 153
on the day of drying-off to 44 on day 6 after drying-off. The inhibition of bacterial
growth depends on the value of the molar ratio: the smaller the molar citrate-to-Lf
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ratio, the more effective the inhibition (Bishop et al. 1976). Thus, increasing the
amount of Lf in milk during the early drying-off by using exogenous Lf could
shift the ratio to be less favourable for bacterial growth.
Kai and co-workers (2002b) have shown that Lf treatment for staphylococcal
mastitis in the early non-lactating period results in higher cure rates than
antimicrobial treatment. The cure rate reported was 92%, which was due to
bacteriostatic or bactericidal effects as well as to the induction of the innate
immunity of the host. This cure rate is in contrast to the 48% cured with
antimicrobials over the same 7-day time frame. Cell population in the cured udder
quarters contained mainly phagocytes, including PMNs and cells positive for
CD11b, which is known to be a complement receptor. The authors speculated that
locally infused Lf promoted the migration of PMNs by inducing the expression of
such cytokines as IL-1ß and IL-8. We agree with their vision of clinical
applications for Lf in mastitis during drying-off. Exogenous udder infusion of Lf
as a dry-cow therapy in a long-acting formula, possible in combination with
antimicrobial agents, may enhance the defence mechanisms of the cow and help
limit bacterial growth in the udder. Another potential application for exogenous
Lf is prevention of infections in the first days after drying-off, probably used
without antimicrobial agents. Experiments for dose determination and
pharmaceutical formulation of Lf for possible combination with antimicrobials or
bicarbonate to overcome the effect of citrate are still needed.
During the non-lactating period most iron in the bovine mammary gland is bound
to Lf, and coliform mastitis rarely occurs in the fully involuted mammary gland.
However, one problem is that some Gram-negative bacteria can overcome the
iron-limiting effect of Lf by using their iron acquisition systems like enterobactin.
The enterobactin receptor FepA acts in the transportation and deferration of ferric
enterobactin (Lin et al. 1998). It can be hypothesized that if coliform mastitis
occurs during the dry period, it may be due to strains which possess mechanism
such as FepA and enterobactin. FepA has been studied for possible development
of a specific vaccine against E. coli mastitis during the dry period (Lin et al.
1999).
Lf had an in vitro antibacterial effect against some major udder pathogens, as also
shown in many earlier studies (Nonnecke & Smith 1984b, Rainard 1986, Diarra et
al. 2003). The best inhibitory activity was against E. coli and P. aeruginosa.
Variable results were seen against the other important udder pathogens S. aureus,
CNS and K. pneumoniae.
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The strong in vitro inhibitory activity of Lf against E. coli was in agreement with
many previous studies (Nonnecke & Smith 1984b, Rainard 1986, Dionysius et al.
1993, Diarra et al. 2003), but contradictory results have also been reported
(Sanchez & Watts 1999). Rainard (1986) tested the in vitro susceptibility of 35 E.
coli isolates to Lf, which had originally been isolated from clinical or subclinical
bovine mastitis. Most of the isolates were completely inhibited. A few isolates
partially resisted the bacteriostatic action of Lf, but none was totally resistant.
Nonnecke & Smith (1984b) reported bacteriostatic, but not bactericidal, activity
of bovine Lf against mastitis-causing isolates of E. coli and K. pneumoniae.
Dionysius et al. (1993) reported that an Lf concentration of 1.0 mg/ml inhibited
growth of all 19 isolates of enterotoxigenic E. coli isolated from porcine enteritis.
They found the degree of inhibition to be strain-dependent and bacterial killing to
occur at relatively high initial concentrations of bacteria. We used 0.67, 1.67, and
2.67 mg/ml concentrations of Lf to compare the inhibitory activity of Lf, and also
observed concentration- and strain-dependency. Despite extensive research on
these antibacterial effects in vitro, their role in vivo remains controversial. In vitro
experiments showing inhibition of growth through iron sequestration cannot
mimic the complex interactions occurring during infection in vivo, when iron is
available from a much wider range of sources, including haemoglobin, to which
Lf cannot bind (Brock 2002). Diarra and co-workers (2003) tested inhibition of
two clinical isolates of S. aureus from bovine mastitis with Lf in vitro and in vivo,
alone and in combination with penicillin G. Their data both in vitro and in vivo in
a mouse mastitis model suggested that Lf is as effective as penicillin G against S.
aureus.
We focused on native Lf because the cost of purifying apo-Lf would limit this
agent’s use in treating bovine mastitis. Whey, prepared from milk of healthy
cows, was used as a growth medium in the in vitro studies since it simulates the
environment of the milk compartment of the cow’s udder. Unfortunately, E. coli
was unable to grow in whey prepared from milk of healthy cows. This has also
been described earlier (Maisi et al. 1984); whey is known to inhibit the growth of
a number of bacterial species. Whey prepared from milk of mastitic cows may
have been a better medium, but standardizing this medium would have been
difficult.
Based on the results of our in vitro studies, we decided to focus on E. coli
mastitis, which still posses a major challenge for the dairy industry, while P.
aeruginosa and K. pneumoniae have less prominent roles. Since E. coli infection
remains in the milk compartment, it is a good target of intramammary treatment
with Lf. S. aureus and perhaps some CNS bacteria cause deep infections in the
udder gland, and it was difficult to predict how the exogenous Lf would spread in
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the udder. The internalization of S. aureus in neutrophils and epithelial cells
would also have been problematic, despite Lf enhancing phagocytosis and
intracellular killing (Diarra et al. 2003). Finally, E. coli was chosen because of the
LPS-neutralizing capacity of Lf against Gram-negative bacteria.
We found that a 1-g dose of Lf infused into the udder quarter increased Lf
concentrations close to those found in mastitic milk; these concentrations are
within the effective range, not too low or too high. Excessively low
concentrations, e.g. 0.5 mg/ml, have no therapeutic effect. Excessively high
concentrations, e.g. 12 mg/ml, cause moderate to severe irritation reactions in
udder quarters and may even disturb or destroy the normal function of the
epithelial cells of the udder. However, Lf concentrations are much higher during
the middle of the non-lactating period than in the early non-lactating period, when
the udder is very resistant to coliform infections (Smith et al. 1985, Oliver &
Bushe 1987). Kai and co-workers (2002a) have shown that a high concentration
of Lf (1 mg/ml) promotes phagocytic activity in the mammary gland. The mean
elimination half-life of exogenous Lf of 2.2 h was shorter than optimal;
antibacterial effects might be enhanced with a half-life of 4 to 6 h.
The udder size, which is related to the age of the cows, was found to influence Lf
concentrations. Udder volume is normally larger and milk yield higher in older
cows than in primiparous cows, and the dilution effect of exogenous Lf might be
different in older cows. After reaching a peak, Lf concentrations decreased faster
in younger cows. This could be due to the smaller udder size of younger cows,
and thus, the smaller gland cistern and milk volume of the udder. Lf may have
been more concentrated in the distal parts of the udder quarter, being removed
while collecting milk samples. Differences of blood circulation in younger and
older cows would also have a role in removing the exogenous Lf. Endogenous Lf
in blood and released by neutrophils, and probably exogenous Lf infused into the
udder quarters, is transported to the liver, where it is taken up by specific
receptors and metabolized (McAbee & Esbensen 1993). Interestingly, Lf
concentrations decreased to normal concentrations in four out of six cows within
8 h of Lf administration, but at 48 h, the concentrations in the older cows were
again several-fold higher than in milk samples taken before administration. This
rise is most likely due to endogenous Lf production, which results from the cow’s
foreign body reaction to the administered protein, thus stimulating the granules of
PMN to release endogenous Lf into the udder. However, in the primiparous cows,
Lf concentrations remained at normal concentrations 48 h after administration,
which is difficult to explain. In milk samples taken at 1, 2 and 4 h after exogenous
Lf infusion, measured Lf concentrations exceeded the infusion concentration. One
explanation for this may be that as a water-soluble substance the exogenous Lf
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did not spread throughout the milk compartment of the infused udder quarter, but
remained in the gland and teat cisterns. Formation of endogenous Lf may also
play a role in the elevated Lf concentrations in older cows.
Intramammary infusion of Lf caused local reactions in the udder quarters. This
could be due to a foreign body reaction of the udder against exogenous protein.
Another explanation for the udder irritation could be contamination of Lf with
endotoxin, provoking an inflammatory reaction. The 1-g dose of Lf used here
contained small quantities of endotoxin, which could partly be responsible for the
mild local reactions. It is impossible to purify endotoxin-free Lf from whey.
However, the low amounts of endotoxin and mild irritation reactions caused by
exogenous Lf would have been irrelevant in severe forms of E. coli mastitis, when
huge amounts of endotoxin are released.
Based on the results of the disposition kinetic studies, we concluded that a 1-g
dose of Lf is insufficient to examine its impact over a longer period. Thus, we
decided to use a 1.5-g doses in the experimental E. coli mastitis study. Because of
local irritation, increasing the dose further was not possible. We therefore chose
to use three doses at 12-h intervals to extend the period of therapeutic Lf
concentrations in milk so that Lf would have better clearance of bacteria and
elimination of LPS. Since the degree of irritation caused by these three 1.5-g
doses of Lf to the mastitic udder quarters was unclear, we did not use a longer
treatment. While the approach not to conduct repeated-dose disposition kinetic
studies could be criticized, carrying out these studies would have been
economically impossible. Unfortunately, well-controlled in vivo experiments
using physiologically relevant concentrations of Lf are lacking.
No significant differences were observed in the outcome of mastitis between
cows treated with Lf and those receiving enrofloxacin; however, bacteria were
eliminated faster in the cows treated with enrofloxacin. The three cows treated
with Lf at the first challenge had lower bacterial counts after the second
challenge. The rapid immune response of the host probably eliminated bacteria
from the udder before the treatment with enrofloxacin was started. One
explanation for the rapid immune response may be longer persistence of bacteria
in the first challenge or a possible immunostimulatory effect of Lf in these cows.
Promptness and extent of response of individual cows to infection largely
determines the prognosis and outcome of coliform mastitis (Shuster et al. 1996,
Hirvonen et al. 1999, Burvenich et al. 2003). In addition, multiparous cows may
be more susceptible to periparturient infectious diseases than primiparous ones
(Mehrzad et al. 2002). Outcome of mastitis and the role of Lf treatment might
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have changed  had we used multiparous cows in our experiment. The effect of Lf
may differ in naturally infected cows diseased soon after parturition, and if four
or more intramammary doses of Lf are used. Combining Lf with some carefully
selected antimicrobial agents could limit the growth of E. coli bacteria better than
Lf alone. The efficacy of Lf was thus not unequivocally confirmed in the present
experiment, and the small size of the treatment groups could be one reason.
Furthermore, our experimental mastitis was induced in vitro with one E. coli
strain susceptible to Lf. In the field, E. coli mastitis can be caused by a variety of
phenotypically or genotypically different strains, and no specific pathogenic
mastitis-causing strains have been identified (Kaipainen et al. 2002). However,
some strains of E. coli are known to circumvent the iron-limiting effect by using
other sources of iron (Lin et al. 1998). For this reason, a 100% effect of Lf will
never occur in spontaneous E. coli mastitis.
Much of the LPS release transpires following bacterial phagocytosis and killing
by neutrophils. Consequently, by the time treatment was initiated, maximal
release of LPS is probably over. We agree with the suggestions by Erskine and co-
workers (1991) that either bacterial growth must be inhibited to reduce the
bacterial exposure of the udder quarter and the cow to LPS, or the effect of the
LPS release must be neutralized to reduce the severity of acute coliform mastitis.
Zhang and co-workers (1999) proposed a human Lf-derived 33-mer synthetic
peptide (Lf-33) to treat endotoxin-induced septic shock. With both in vitro and in
vivo mice models, they showed that survival rate was dramatically increased by
injecting Lf-33 simultaneously with LPS; mortality was reduced from 93% (14/15
animals dead) to 6% (1/15 animals dead). In our experimental study, LPS
concentrations in milk were about 1400 times lower in Lf- than in enrofloxacin-
treated cows, which may indicate the LPS neutralizing effect of Lf infused into
the E. coli-affected udder quarters. Ziv & Schultze (1983) tested in an
experimental endotoxin mastitis model polymyxin B, an antimicrobial drug with
the capacity to neutralize LPS, but failed to find significant beneficial effects with
its administration shortly after LPS.
In some in vitro studies on mastitis pathogens, Lf has been combined with
antimicrobial agents (Sanchez & Watts, 1999, Diarra et al. 2002a, 2003), and a
synergistic effect has been found. Testing Lf alone avoided the problems related
to the use of antimicrobial drugs and allowed the actual net effect of Lf against
several bacterial species in vitro and against experimental E. coli mastitis in vivo
to be determined. Only a few potentially effective antimicrobial drugs exist for
the treatment of severe E. coli mastitis. Enrofloxacin is one of these, but it causes
marked tissue irritation if not administered i.v. (Pyörälä et al. 1994b), as also seen
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in our study. More importantly, fluoroquinolones are valued drugs in human
medicine, and their abundant use in food-producing animals could lead to a
problematic increase in bacterial resistance.
Exogenous Lf, possibly combined with a bicarbonate, would support clearance of
bacteria from the udder while simultaneously blocking the detrimental effects of
LPS. Upon determining the optimal dose, its potential value in treating coliform
mastitis, especially severe E. coli mastitis, is immeasurable. Further
pharmacokinetic studies and field trials are, however, needed to more fully
elucidate its role in the treatment of severe coliform mastitis.
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7. CONCLUSIONS
1. Lf concentrations gradually increased and citrate concentrations decreased in
milk during the first days of the dry period. The Lf and citrate concentrations
markedly varied between cows and even between udder quarters of the same cow;
neither the breed nor the parity of cows affected the concentrations.
2. The in vitro inhibitory activity of Lf against E. coli and P. aeruginosa was good
in the ISB broth. Some inhibitory activity was found also against S. aureus. The
activity of Lf against CNS was variable and no significant effects were seen.
3. Intramammary administration of one gram of Lf produced elevated Lf
concentrations in milk for several hours. Udder size, which is related to the age of
cows, influenced the concentrations.
4. Exogenous Lf infusion was tolerated quite well, and only mild local reactions
were recorded in udder quarters.
5. Intramammarily infused Lf may have a LPS neutralizing effect in experimental
mastitis induced with E. coli; LPS concentrations in milk were about 1400 times
lower in Lf- than in antimicrobial-treated cows.
6. Lf may offer an alternative treatment for severe coliform mastitis. Further
studies using different dosages of Lf are, however, needed before conclusions can
be drawn on the therapeutic value of Lf in E. coli mastitis.
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